Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial

Marc A Pfeffer, Brian Claggett, Eldrin F Lewis, Christopher B Granger, Lars Køber, Aldo P Maggioni, Douglas L Mann, John J V McMurray, Jean-Lucien Rouleau, Scott D Solomon, Philippe Gabriel Steg, Otavio Berwanger, Maja Cikes, Carmine G De Pasquale, Alberto Fernandez, Gerasimos Filippatos, Karola Jering, Ulf Landmesser, Venugopal Menon, Béla Merkely, Mark C Petrie, Ivo Petrov, Morten Schou, Michele Senni, David Sim, Peter van der Meer, Martin Lefkowitz, Yinong Zhou, Yi Wang, Eugene Braunwald, Marc A Pfeffer, Brian Claggett, Eldrin F Lewis, Christopher B Granger, Lars Køber, Aldo P Maggioni, Douglas L Mann, John J V McMurray, Jean-Lucien Rouleau, Scott D Solomon, Philippe Gabriel Steg, Otavio Berwanger, Maja Cikes, Carmine G De Pasquale, Alberto Fernandez, Gerasimos Filippatos, Karola Jering, Ulf Landmesser, Venugopal Menon, Béla Merkely, Mark C Petrie, Ivo Petrov, Morten Schou, Michele Senni, David Sim, Peter van der Meer, Martin Lefkowitz, Yinong Zhou, Yi Wang, Eugene Braunwald

No abstract available

Keywords: heart failure; myocardial infarction; ramipril; sacubitril/valsartan.

Figures

Figure 1.

Clinical Outcomes. Shown are Kaplan-Meier curves for the investigator-reported primary composite outcome, analyzed as time to first (A), and Nelson-Aalen event curves for total (first and recurrent) CEC adjudicated (B) and investigator-reported (C) primary events of total hospitalizations for heart failure, total outpatient episodes of symptomatic heart failure and cardiovascular death. (A) Investigator-reported time-to-first event: 443 patients (15.7%) in the sacubitril/valsartan group (cardiovascular death: 115, hospitalization: 231 and outpatient: 97) and 516 patients (18.2%) in the ramipril group (cardiovascular death: 111, hospitalization: 264 and outpatient: 141). (B) CEC adjudicated total primary events: 452 primary events in the sacubitril/valsartan group (240 hospitalizations, 44 outpatient episodes and 168 cardiovascular deaths) and 539 events in the ramipril group (286 hospitalizations, 62 outpatient episodes and 191 cardiovascular deaths). (C) Investigator-reported total primary events: 672 primary events in the sacubitril/valsartan group (395 hospitalizations, 122 outpatient episodes and 155 cardiovascular deaths) and 802 events in the ramipril group (447 hospitalizations, 176 outpatient episodes and 179 cardiovascular deaths).

Figure 1.

Clinical Outcomes. Shown are Kaplan-Meier curves for the investigator-reported primary composite outcome, analyzed as time to first (A), and Nelson-Aalen event curves for total (first and recurrent) CEC adjudicated (B) and investigator-reported (C) primary events of total hospitalizations for heart failure, total outpatient episodes of symptomatic heart failure and cardiovascular death. (A) Investigator-reported time-to-first event: 443 patients (15.7%) in the sacubitril/valsartan group (cardiovascular death: 115, hospitalization: 231 and outpatient: 97) and 516 patients (18.2%) in the ramipril group (cardiovascular death: 111, hospitalization: 264 and outpatient: 141). (B) CEC adjudicated total primary events: 452 primary events in the sacubitril/valsartan group (240 hospitalizations, 44 outpatient episodes and 168 cardiovascular deaths) and 539 events in the ramipril group (286 hospitalizations, 62 outpatient episodes and 191 cardiovascular deaths). (C) Investigator-reported total primary events: 672 primary events in the sacubitril/valsartan group (395 hospitalizations, 122 outpatient episodes and 155 cardiovascular deaths) and 802 events in the ramipril group (447 hospitalizations, 176 outpatient episodes and 179 cardiovascular deaths).

Figure 1.

Clinical Outcomes. Shown are Kaplan-Meier curves for the investigator-reported primary composite outcome, analyzed as time to first (A), and Nelson-Aalen event curves for total (first and recurrent) CEC adjudicated (B) and investigator-reported (C) primary events of total hospitalizations for heart failure, total outpatient episodes of symptomatic heart failure and cardiovascular death. (A) Investigator-reported time-to-first event: 443 patients (15.7%) in the sacubitril/valsartan group (cardiovascular death: 115, hospitalization: 231 and outpatient: 97) and 516 patients (18.2%) in the ramipril group (cardiovascular death: 111, hospitalization: 264 and outpatient: 141). (B) CEC adjudicated total primary events: 452 primary events in the sacubitril/valsartan group (240 hospitalizations, 44 outpatient episodes and 168 cardiovascular deaths) and 539 events in the ramipril group (286 hospitalizations, 62 outpatient episodes and 191 cardiovascular deaths). (C) Investigator-reported total primary events: 672 primary events in the sacubitril/valsartan group (395 hospitalizations, 122 outpatient episodes and 155 cardiovascular deaths) and 802 events in the ramipril group (447 hospitalizations, 176 outpatient episodes and 179 cardiovascular deaths).